Infant Bacterial Therapeutics AB (publ) (IBT-B.ST) Research

Infant Bacterial Therapeutics AB (publ) is a biopharmaceutical company in the clinical development phase, specializing in creating treatments for serious and uncommon conditions that impact prematurely born infants. Based in Stockholm, Sweden, and established in 2013, the company's primary therapeutic candidate is IBP-9414, which aims to both prevent necrotizing enterocolitis (NEC) – a severe intestinal disease – and enhance digestive tolerance in these vulnerable newborns. Additionally, they are progressing IBP-1016, designed to address gastroschisis, a critical congenital defect affecting infants.

Market snapshot

Symbol
IBT-B.ST
Price
$63.00
Day change
-4.69%
Market cap
$820.1M
P/E ratio
-11.89x
52-week range
43.25-84.3
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months

Peer companies

  • ADDvise Group AB (publ) (ADDV-B.ST)
  • Cantargia AB (publ) (CANTA.ST)
  • Corline Biomedical AB (CLBIO.ST)
  • Guard Therapeutics International AB (publ) (GUARD.ST)
  • I-Tech AB (ITECH.ST)
  • Oncopeptides AB (publ) (ONCO.ST)
  • Senzime AB (publ) (SEZI.ST)
  • SynAct Pharma AB (SYNACT.ST)

Open Infant Bacterial Therapeutics AB (publ) (IBT-B.ST) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.